Earnings
Esperion announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open..
CELLINK publishes the quarterly report for the period 1st of June 2019 – 31st of August 2019 and for the full year of operations 2018-2019.
BioArctic and Eisai presented new data regarding BAN2401 at the Alzheimer’s Association International Conference® (AAIC®) in July that confirmed BAN2401’s unique characteristics and was consistent with previously presented results
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced third quarter revenue and net cash position as of September 30, 2019.
MorphoSys AG will publish its first nine months’ 2019 results on October 29, 2019 at 10:00pm CET
Pharnext SA, a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomics data and artificial intelligence, announced its financial results for first-half 2019.
Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care
Sydney, Australia, 10 October 2019: Recce Pharmaceuticals Ltd, developing a new class of synthetic antibiotics, is pleased to announce it has raised AU$6,768,444.28 in a placement to institutional, professional and sophisticated investors that will result in 26,032,478 fully paid ordinary shares being issued at AU$0.26 per share
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group’s financial figures.
Sareum Holdings plc, the specialised small molecule drug development business, will announce its results for the full year ended 30 June 2019 on Tuesday 15 October.
PRESS RELEASES